Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare 10 mg of an Oral Suspension of Rivaroxaban Under Fasting (2 Different Batches) and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions in Healthy Subjects

Trial Profile

Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare 10 mg of an Oral Suspension of Rivaroxaban Under Fasting (2 Different Batches) and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov:
    • 01 Jun 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-001720-19).
    • 21 May 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top